Literature DB >> 18440462

CT-guided radiofrequency ablation in the palliative treatment of recurrent advanced head and neck malignancies.

Allan L Brook1, Menachem M Gold, Todd S Miller, Tamar Gold, Randall P Owen, Laurie S Sanchez, Joaquim M Farinhas, Keivan Shifteh, Jacqueline A Bello.   

Abstract

PURPOSE: To evaluate the safety and effectiveness of computed tomography (CT)-guided radiofrequency (RF) ablation in the palliative treatment of recurrent advanced head and neck cancers.
MATERIALS AND METHODS: From November 2002 to January 2005, the authors identified 14 patients (median age, 61 years) with 14 recurrent advanced primary head and neck malignancies who underwent 27 CT-guided RF ablation applications during 20 sessions at their institution. RF ablation was performed in all patients with the intent of palliative therapy. Radiologic tumor response was assessed by using Response Evaluation Criteria in Solid Tumors. Patients were assessed clinically by means of University of Washington Head and Neck Quality of Life questionnaires.
RESULTS: Technical success in tumor targeting and electrode deployment was 100%. University of Washington quality of life surveys completed by six of 14 patients (43%) showed an index increase by a median of 3.1 percentage points, with four of six patients (67%) demonstrating improvement. Three major complications (in 27 applications, 11%) occurred 7 days to 2 weeks after the procedure. These included stroke, carotid blowout leading to death, and threatened carotid blowout with subsequent stroke. Retrospective analysis of intraprocedural CT scans revealed that the retractable electrodes were within 1 cm of the carotid artery during ablation in these cases.
CONCLUSIONS: RF ablation in patients with advanced head and neck malignancies is feasible and effective for palliation. CT-guidance provides accurate probe placement and electrode deployment. The energy level used and proximity of the ablation sphere to the carotid artery may predispose to vascular complications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18440462     DOI: 10.1016/j.jvir.2007.12.439

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  7 in total

1.  [Radiofrequency ablation as a palliative therapy option in ENT tumors: in vivo and in vitro testing].

Authors:  S Bucher; J Hornung; V Bonkowsky; H Iro; J Zenk
Journal:  HNO       Date:  2010-04       Impact factor: 1.284

2.  Radiofrequency ablation in advanced head and neck cancer.

Authors:  Randall P Owen; Jane S Lee; Carl E Silver; Leif Bäck; Jonathan J Beitler; Alessandra Rinaldo; Bert W O'Malley; Missak Haigentz; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-09-24       Impact factor: 2.503

Review 3.  Interventional neuroradiology of the head and neck.

Authors:  D Gandhi; J J Gemmete; S A Ansari; S K Gujar; S K Mukherji
Journal:  AJNR Am J Neuroradiol       Date:  2008-09-10       Impact factor: 3.825

4.  Percutaneous Image-Guided Cryoablation of Head and Neck Tumors for Local Control, Preservation of Functional Status, and Pain Relief.

Authors:  Jeffrey P Guenette; Kemal Tuncali; Nathan Himes; Paul B Shyn; Thomas C Lee
Journal:  AJR Am J Roentgenol       Date:  2016-11-15       Impact factor: 3.959

Review 5.  A Technical Guide to Palliative Ablation of Recurrent Cancers in the Deep Spaces of the Suprahyoid Neck.

Authors:  Terrence Chi Hong Hui; Ming Yann Lim; Amit Anand Karandikar; Siu Cheng Loke; Uei Pua
Journal:  Semin Intervent Radiol       Date:  2022-06-30       Impact factor: 1.780

Review 6.  Percutaneous Management of Recurrent Head and Neck Cancer: Current Role and Evolving Principles in the Multidisciplinary Setting.

Authors:  Lawrence Han Hwee Quek; Ming Yann Lim; Timothy Cheo; Hui Lin Teo; Uei Pua
Journal:  Curr Oncol Rep       Date:  2021-03-22       Impact factor: 5.075

Review 7.  A short review of basic head and neck interventional procedures in a general radiology department.

Authors:  H Y Yuen; Y Y P Lee; K Bhatia; A T Ahuja
Journal:  Cancer Imaging       Date:  2013-12-11       Impact factor: 3.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.